Literature DB >> 28280888

Respiratory depression related to multiple drug-drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone.

Bruno Charpiat1,2, Michel Tod3, Benjamin Darnis4, Guillaume Boulay5, Marie-Claude Gagnieu6, Jean-Yves Mabrut4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28280888     DOI： 10.1007/s00228-017-2215-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  15 in total

1.  Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Authors:  Michel Tod; Christina Nkoud-Mongo; François Gueyffier
Journal:  AAPS J       Date:  2013-09-12       Impact factor: 4.009

2.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

3.  Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey.

Authors:  Masaaki Watanabe; Masato Homma; Kenji Momo; Yasushi Okoshi; Tetsuro Wada; Akira Hara; Shigeru Chiba; Yukinao Kohda
Journal:  Eur J Clin Pharmacol       Date:  2011-01-08       Impact factor: 2.953

4.  Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.

Authors:  David E Moody; Fenyun Liu; Wenfang B Fang
Journal:  J Anal Toxicol       Date:  2015-04-12       Impact factor: 3.367

5.  Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-11-04       Impact factor: 3.533

6.  Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.

Authors:  Tuija H Nieminen; Nora M Hagelberg; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2010-08-10       Impact factor: 2.953

7.  Fluconazole: a potent inhibitor of cytochrome P-450-dependent drug-metabolism in mice and humans in vivo. Comparative study with ketoconazole.

Authors:  K Morita; H Konishi; H Shimakawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-05       Impact factor: 1.645

8.  Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.

Authors:  Teijo I Saari; Juha Grönlund; Nora M Hagelberg; Mikko Neuvonen; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2010-04       Impact factor: 2.953

9.  Pregabalin Has Analgesic, Ventilatory, and Cognitive Effects in Combination with Remifentanil.

Authors:  Marianne Myhre; Lien My Diep; Audun Stubhaug
Journal:  Anesthesiology       Date:  2016-01       Impact factor: 7.892

10.  Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.

Authors:  Bojan Lalovic; Brian Phillips; Linda L Risler; William Howald; Danny D Shen
Journal:  Drug Metab Dispos       Date:  2004-04       Impact factor: 3.922
View more
  1 in total

1.  Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Authors:  Nicolas Fermier; Laurent Bourguignon; Sylvain Goutelle; Nathalie Bleyzac; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.